Barclays PLC Avita Medical, Inc. Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Avita Medical, Inc. stock. As of the latest transaction made, Barclays PLC holds 19,631 shares of RCEL stock, worth $73,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,631

Previous 46,559 57.84%

Holding current value

$73,616

Previous $247,000 59.92%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$4.17 - $6.76 $112,289 - $182,033	-26,928 Reduced 57.84%	19,631 $99,000
Q2 2025 Aug 13, 2025	BUY	$4.77 - $10.25 $84,743 - $182,101	17,766 Added 61.7%	46,559 $247,000
Q1 2025 May 15, 2025	SELL	$8.14 - $13.72 $99,601 - $167,877	-12,236 Reduced 29.82%	28,793 $234,000
Q4 2024 Feb 13, 2025	BUY	$9.89 - $13.7 $34,872 - $48,306	3,526 Added 9.4%	41,029 $525,000
Q3 2024 Nov 15, 2024	BUY	$7.72 - $10.87 $223,717 - $315,001	28,979 Added 339.97%	37,503 $402,000

Q2 2024 Aug 14, 2024	SELL	$7.92 - $15.55 $93,551 - $183,676	-11,812 Reduced 58.08%	8,524 $68,000
Q1 2024 May 15, 2024	SELL	$12.56 - $18.31 $177,648 - $258,976	-14,144 Reduced 41.02%	20,336 $325,000
Q4 2023 Feb 15, 2024	BUY	$9.29 - $14.57 $280,028 - $439,183	30,143 Added 695.02%	34,480 $473,000
Q3 2023 Nov 07, 2023	SELL	$13.84 - $20.79 $9,286 - $13,950	-671 Reduced 13.4%	4,337 $63,000
Q2 2023 Aug 03, 2023	BUY	$10.7 - $17.48 $53,585 - $87,539	5,008 New	5,008 $85,000
Q2 2022 Aug 12, 2022	SELL	$4.6 - $8.82 $17,728 - $33,992	-3,854 Reduced 97.72%	90 $0
Q1 2022 May 16, 2022	BUY	$6.96 - $12.15 $27,450 - $47,919	3,944 New	3,944 $34,000

Others Institutions Holding RCEL

# of Institutions

Shares Held

5.81M

Call Options Held

77.4K

Put Options Held

19.4K

View Full List

About AVITA Medical, Inc.

Ticker RCEL
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 25,030,900
Market Cap $93.9M
Description
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...

More about RCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account